CINECA IRIS Institutional Research Information System

BERTINARIA, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3531
EU - Europa 2306
AS - Asia 1068
AF - Africa 27
OC - Oceania 16
SA - Sud America 16
Continente sconosciuto - Info sul continente non disponibili 5
Totale 6969
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3449
CN - Cina 716
IT - Italia 581
IE - Irlanda 327
SE - Svezia 289
DE - Germania 186
UA - Ucraina 186
GB - Regno Unito 144
FR - Francia 136
FI - Finlandia 115
KR - Corea 100
VN - Vietnam 87
PL - Polonia 86
CA - Canada 71
AT - Austria 66
JP - Giappone 49
BE - Belgio 45
DK - Danimarca 43
IN - India 43
CH - Svizzera 19
AU - Australia 15
RO - Romania 14
SN - Senegal 14
RU - Federazione Russa 12
HK - Hong Kong 11
IR - Iran 11
ES - Italia 10
GR - Grecia 10
MX - Messico 10
BR - Brasile 8
NL - Olanda 8
UZ - Uzbekistan 8
IL - Israele 7
TW - Taiwan 7
TH - Thailandia 6
TR - Turchia 6
EU - Europa 5
HU - Ungheria 5
AL - Albania 4
CL - Cile 4
CZ - Repubblica Ceca 4
ID - Indonesia 4
MY - Malesia 4
NO - Norvegia 4
PT - Portogallo 4
EG - Egitto 3
NG - Nigeria 3
RS - Serbia 3
IQ - Iraq 2
PK - Pakistan 2
SA - Arabia Saudita 2
SC - Seychelles 2
VE - Venezuela 2
ZA - Sudafrica 2
AM - Armenia 1
AR - Argentina 1
BG - Bulgaria 1
BJ - Benin 1
DZ - Algeria 1
EC - Ecuador 1
EE - Estonia 1
LT - Lituania 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
SG - Singapore 1
SK - Slovacchia (Repubblica Slovacca) 1
UG - Uganda 1
YE - Yemen 1
Totale 6969
Salva come PNG Salva come JPEG
Città #
Chandler 678
Ann Arbor 408
Dublin 323
Beijing 299
Fairfield 228
Torino 172
Houston 152
Jacksonville 149
Wilmington 142
Woodbridge 133
Nyköping 106
Ashburn 104
Dearborn 99
Seattle 89
Medford 88
Redwood City 87
Pisa 84
Villeurbanne 84
Princeton 81
Warsaw 75
Cambridge 74
Vienna 66
Dong Ket 62
Fremont 48
Shanghai 45
Guangzhou 40
Brussels 39
Milan 39
Turin 38
Nanjing 33
Boardman 26
Boston 24
Toronto 24
Rome 23
Ottawa 22
San Diego 22
Hangzhou 21
Munich 20
Shenyang 19
Hefei 18
Zhengzhou 18
Jinan 15
Seongnam 15
Chengdu 13
Lansing 12
Verona 12
Xian 12
Philadelphia 10
Seoul 10
Tokyo 10
Wuhan 10
Changsha 9
Fuzhou 9
Hebei 9
Norwalk 9
Nottingham 9
Pittsburgh 9
Lachine 8
Athens 7
Hanover 7
Mountain View 7
Düsseldorf 6
Harbin 6
London 6
New York 6
Phoenix 6
Rochester 6
Taipei 6
Tübingen 6
Bari 5
Bologna 5
Chieti 5
Falls Church 5
Hamburg 5
Hyderabad 5
Menlo Park 5
Monmouth Junction 5
San Mateo 5
Santa Clara 5
Silver Spring 5
Belfast 4
Chongqing 4
Cluj-napoca 4
Copenhagen 4
Dresden 4
Duncan 4
Gent 4
Helsinki 4
Kunming 4
Leinì 4
Miami 4
Mumbai 4
Nanchang 4
Nußloch 4
Sagamihara 4
Temecula 4
Tianjin 4
Alessandria 3
Ardabil 3
Aurora 3
Totale 4684
Salva come PNG Salva come JPEG
Nome #
Electrophilic Warhead-Based Design of Compounds Preventing NLRP3 Inflammasome-Dependent Pyroptosis 521
In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition 297
Stable Oxidative Cytosine Modifications Accumulate in Cardiac Mesenchymal Cells from Type2 Diabetes Patients: Rescue by alpha Ketoglutarate and TET-TDG Functional Reactivation 292
Pharmacological inhibition of NLRP3 inflammasome attenuates myocardial ischemia/reperfusion injury by activation of RISK and mitochondrial pathways 282
Designing Multitarget Anti-inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists-COX-2 Inhibitors. 250
Is NLRP3 inflammasome a new pharmacological target in myocardial ischemia/reperfusion injury? 248
Development of covalent NLRP3 inflammasome inhibitors: chemistry and biological activity 210
A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity 208
Carnosine analogues containing NO-donor substructures: Synthesis, physico-chemical characterization and preliminary pharmacological profile 188
Edaravone derivatives containing NO-donor functions 183
Amodiaquine analogues containing NO-donor substructures: Synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria 138
Nonsteroidal anti-inflammatory drugs: Exploiting bivalent COXIB/TP antagonists for the control of cardiovascular risk 135
α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis 133
A rapid screening for cytochromes P450 catalysis on new chemical entities: cytochrome P450 BM3 and 1,2,5-oxadiazole derivatives 119
A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation 118
Design, Synthesis, and Evaluation of Acrylamide Derivatives as Direct NLRP3 Inflammasome Inhibitors 115
Design and synthesis of N-benzoyl amino acid derivatives as DNA methylation inhibitors 111
Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents 105
Amphiphilic NO-Donor Antioxidants 104
Composti ibridi per il trattamento della malaria cerebrale 103
Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease 103
A new class of NO-donor H3-Antagonists 102
NO-Donor Phenols: A New Class of Products Endowed with Antioxidant and Vasodilator Properties 98
Design, Synthesis and Pharmacological Evaluation of Anti-Pyroptotic Compounds Acting on NLRP3 Inflammasome Signaling Pathway: a New Start for Anti-Inflammatory Drugs? 97
Cardiac Epi-Metabolic Signature Revealed by Integrated Omics Approach in Diabetic Patients: Rescue by Active DNA Demethylation via TET-TDG Complex Reactivation 94
Synthesis of Small Molecules as Potential DNA Methylation Modulators 93
Carnosine analogues containing Phenol substructures 92
[3-(1H-Imidazol-4-yl)propyl)guanidines Containing Furoxan Moieties: A New Class of H3-Antagonists Endowed with NO-Donor Properties 87
EXPLORING THE AMYLOID BETA (ABETA) DEPENDENT METABOLIC FINGERPRINT OF HIPPOCAMPAL NEURONS BY TWO-DIMENSIONAL COMPREHENSIVE GAS CHROMATOGRAPHY: POTENTIALS IN DRUG DISCOVERY STUDIES 85
Different multitarget approaches to manage coxibs associatedcardiovascular risk. Design and synthesis of new lumiracoxibderivatives 82
Synthesis and pharmacological characterisation of new H2-antagonists containing NO-donor moieties, endowed with mixed antisecretory and gastroprotective activities. 81
Anti-Helicobacter pylori Agents Endowed with H2-antagonist Properties 78
A multitarget approach to optimize the safety profile of coxibs: lumiracoxib derivatives with dual cyclooxygenase-2 inhibitor-thromboxane A2 receptor antagonist activity 76
Use of the furoxan (1,2,5-oxadiazole 2-oxide)system in the design of new NO-donor antioxidant hybrids 75
Use of the Morita-Baylis-Hillman reaction in the design of compounds inhibiting NLRP3 inflammasome signaling pathways 75
Furoxan analogues of the histamine H3-receptor antagonist imoproxifan and related furazan derivatives 74
Chemical modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2h-benzo[d]imidazole-2-one scaffold as a novel NLRP3 inhibitor 73
Use of the furoxan (1,2,5-oxadiazole 2-oxide) system in the design of new NO-donor antioxidant hybrids 72
Synthesis and antimalarial activities of some furoxan sulfones and related furazans 72
Targeting NLRP3 inflammasome regulatory mechanisms: design of anti-pyroptotic compounds for autoinflammatory diseases 70
Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades 69
Targeting of NLRP3 Inflammasome With a Novel Selective Inhibitor as a Suitable Strategy for the Pharmacological Treatment of Bowel Inflammation 67
Antisecretory and gastroprotective activities of compounds endowed with H2 antagonistic and nitric oxide (NO) donor properties 66
Synthesis, physico-chemical characterization, andbiological activities of new carnosine derivatives stablein human serum as potential neuroprotective agents 66
In the search for new NLRP3 inhibitors: chemical modulation of the 1-(piperidin-4-yl)-1,3-dihydro-2 Hbenzo[d]imidazole-2-one scaffold 65
Pharmacological characterization of new NLRP3 inflammasome inhibitors. 63
Unsymmetrically substituted furoxans. Part 18. Smiles rearrangement in furoxan systems and in related furazans 61
NO-donor Carnosine Derivatives As Potential Neuroprotective Agents 60
Do P2Y12 receptor antagonism and NLRP3 inhibition exert additive cardioprotective effects against ischemia/reperfusion injury? 59
Synthesis and preliminary evaluation of model compounds targeting the NLRP3 inflammasome pathways 56
Furoxan-, alkylnitrate-derivatives and related compoundsas anti-trypanosomatid agents: Mechanism of action studies 56
NO-Donor Dihydroartemisinin Derivatives as Multitarget Agents for the Treatment of Cerebral Malaria 55
H3 receptor ligands: new imidazole H3-antagonists endowed with NO-donor properties 54
Effect of the leaving group on the electrodic reduction mechanism of anti-Helicobacter pylori metronidazole derivatives, in aprotic and protic media 54
Inhibition of NLRP3 ATPase activity: a new strategy to fight chronic inflammatory diseases 54
Identification of Small Synthetic Anti-Pyroptotic Compounds 53
Synthesis and Pharmacological Evaluation of Novel H3 Antagonists Endowed with NO-Donor Properties 51
A New Gateway for Rheumatoid Arthritis: COXIBs with an Improved Cardiovascular Profile 51
Progettazione, sintesi ed attività farmacologica di nuovi ibridi molecolari NO-donatori attivi sul recettore H2 dell'istamina 47
Breakthroughs in medicinal chemistry: New targets and mechanisms, new drugs, new hopes-7 46
Evidence of self-protonation on the electrodic reduction mechanism of an anti-Helicobacter pylori metronidazole isostere 45
Targeting NLRP3 inflammasome: development of new covalent and non-covalent inhibitors of ATPase activity 43
New tools for the development of direct NLRP3 inflammasome inhibitors 41
Structure-Antioxidant Activity Relationships in a Series of NO-Donor Phenols 41
In silico study of NLRP3: towards selective inhibition with small molecules 41
Non-imidazole histamine NO-donor H3-antagonists 40
NEW NON-COVALENT INHIBITORS OF NLRP3 INFLAMMASOME ATPASE ACTIVITY 40
EVALUATION OF THE ANTIPYROPTOTIC ACTIVITY OF NEW INFLAMMASOME INHIBITORS 37
Nitric oxide (NO) donor beta(2)-agonists:furoxan derivatives containing the fenoterol moiety and related furazans 32
COMPOSTI INIBITORI DELL’INFLAMMASOMA NLRP3 E LORO USO 30
H3 Receptor Ligands: New Imidazole H3-antagonists Endowed with NO-Donor Properties 29
Synthesis and anti-helicobacter pylori properties of NO/donor metronidazole hybrids and related compounds 27
Do P2Y12 receptor antagonism and NLRP3 inhibition exert additive cardioprotective effects against ischemia/reperfusion injury? 17
Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein 16
Editorial: Neurological, Metabolic and Inflammatory Disorders: A Common Root in Inflammasome 15
Multitarget antioxidant NO-donor organic nitrates: a novel ap-proach to overcome nitrates tolerance, an ex vivo study 14
Inflammasome Inhibitors 13
Design and synthesis of SWIR emitters for optical imaging 12
Design and synthesis of encorafenib-based BRAF-V600E degraders 10
Inflammasome Biology Fundamentals, Role in Disease States, and Therapeutic Opportunities 1
Totale 7236
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11299
article - articoli 0
book - libri 0
conference - conferenze 2976
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14275
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018550 0000 00 0140 271962617
2018/2019753 28264421 3387 3593 389916683
2019/20201196 604282137 92143 106106 1481256194
2020/20211040 74688366 10484 7763 1426869142
2021/20221305 60798790 8738 9989 6598280233
2022/20231528 16626880234 131479 1700 0000
Totale 7236